Id |
Subject |
Object |
Predicate |
Lexical cue |
T1 |
574-789 |
Epistemic_statement |
denotes |
As the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I, this axis is possibly acting as a counter-regulatory system against the ACE/Ang II/AT 1 receptor axis. |
T2 |
790-887 |
Epistemic_statement |
denotes |
The signaling pathway of the ACE2-Ang-(1-7) axis has not yet been totally and clearly understood. |
T3 |
888-977 |
Epistemic_statement |
denotes |
However, a recent report suggests that the Mas oncogene acts as a receptor for Ang-(1-7). |
T4 |
978-1031 |
Epistemic_statement |
denotes |
Intracellular signaling through Mas is not clear yet. |
T5 |
1032-1205 |
Epistemic_statement |
denotes |
Several factors such as Akt phosphorylation, protein kinase C activation and mitogen-activated protein (MAP) kinase inhibition seem to be involved in this signaling pathway. |
T6 |
1206-1312 |
Epistemic_statement |
denotes |
Further investigations are needed to clarify the regulation and mechanism of action of ACE2 and Ang-(1-7). |
T7 |
1313-1458 |
Epistemic_statement |
denotes |
However, this second axis through ACE2 and Ang-(1-7) in RAS can be an important target for the therapy of cardiovascular and metabolic disorders. |
T8 |
1460-1544 |
Epistemic_statement |
denotes |
The renin-angiotensin system (RAS) has a critical role in the cardiovascular system. |
T9 |
2120-2254 |
Epistemic_statement |
denotes |
3 In cardiovascular diseases, AT 2 -receptor stimulation seems to antagonize the signaling associated with AT 1 -receptor stimulation. |
T10 |
2482-2664 |
Epistemic_statement |
denotes |
4 In this context, AT 2 -receptor agonists, such as compound 21, have been newly developed and are expected to function as useful agents against pathological disorders in the future. |
T11 |
2665-2716 |
Epistemic_statement |
denotes |
5 Recently, a new axis of RAS has been established. |
T12 |
2806-2902 |
Epistemic_statement |
denotes |
6, 7 The mechanisms of action of Ang-(1-7) are still being investigated by many research groups. |
T13 |
3409-3513 |
Epistemic_statement |
denotes |
4 Recent studies indicate that Ang II is also involved in the onset of diabetes and metabolic disorders. |
T14 |
3586-3656 |
Epistemic_statement |
denotes |
This classical axis can be called as the ACE-AngII-AT 1 receptor axis. |
T15 |
3657-3763 |
Epistemic_statement |
denotes |
Such findings are closely related to the development of RAS inhibitors, such as the ACE inhibitor and ARB. |
T16 |
4797-4847 |
Epistemic_statement |
denotes |
However, these efforts produced the ACE inhibitor. |
T17 |
5857-5942 |
Epistemic_statement |
denotes |
AT 1 -receptor stimulation seems to activate the EGF receptor in the plasma membrane. |
T18 |
6439-6733 |
Epistemic_statement |
denotes |
[13] [14] [15] ROLES OF ACE2, ANG-(1-7) AND THE MAS AXIS-A NEW RAS PATHWAY Possible effects such as vasodilation mediated by Ang-(1-7) have been reported; however, the mechanisms leading to Ang-(1-7) production and its receptor were unclear, resulting in the delay of Ang-(1-7)based researches. |
T19 |
6993-7133 |
Epistemic_statement |
denotes |
18 As Ang-(1-9) can be converted to Ang-(1-7) by ACE or by other peptidases, ACE2 facilitates Ang-(1-7) production by two separate pathways. |
T20 |
7186-7306 |
Epistemic_statement |
denotes |
It might be possible that Ang-(1-7) is a degradation product of Ang II and one of the inactivation mechanisms of Ang II. |
T21 |
7307-7384 |
Epistemic_statement |
denotes |
However, recent studies indicate that Ang-(1-7) has more active roles in RAS. |
T22 |
7488-7566 |
Epistemic_statement |
denotes |
This effect seemed to be mediated by the bradykinin-NO (nitric oxide) pathway. |
T23 |
7567-7925 |
Epistemic_statement |
denotes |
18, 20 Accordingly, these results suggest that Ang-(1-7) antagonized the pressor effect of AT 1 -receptor stimulation, suggesting that it may act as a kind of AT 1 -receptor antagonist, thereby resulting in a blood-pressure-lowering effect and an organ-protective effect, such as a reduction of cardiac hypertrophy and fibrosis and renal damage ( Figure 3 ). |
T24 |
8663-8902 |
Epistemic_statement |
denotes |
26, 27 It has been discovered that the catalytic efficiency of ACE2 is approximately 400-fold higher with Ang II as a substrate than with Ang I, 17 suggesting that this second arm of the system acts as a counter-regulator of the first arm. |
T25 |
8903-9038 |
Epistemic_statement |
denotes |
Previous reports suggest that olmesartan, an ARB, increased the plasma concentration of Ang-(1-7) and the cardiac ACE2expression level. |
T26 |
9039-9222 |
Epistemic_statement |
denotes |
28, 29 Another ARB, losartan, also induced similar changes; however, its dose was 100-fold higher than that of olmesartan, 28 suggesting that this effect of ARB is not a class effect. |
T27 |
9223-9361 |
Epistemic_statement |
denotes |
A more detailed analysis could show the regulation of ACE2 and Mas, which could contribute toward a new drug discovery for regulating RAS. |
T28 |
9362-9552 |
Epistemic_statement |
denotes |
Recent studies on the function of ACE2 suggest that ACE2 has an important role in the severity of lung failure, such as in acute respiratory distress syndrome (ARDS) or in acute lung injury. |
T29 |
9553-9784 |
Epistemic_statement |
denotes |
30 Moreover, it has been shown that the severe acute respiratory syndrome (SARS) corona virus utilizes ACE2 as an essential receptor for cell fusion and for in vivo infections, suggesting that ACE2 contributes to SARS pathogenesis. |
T30 |
9785-9940 |
Epistemic_statement |
denotes |
31 These results indicate that ACE2 activity has an important role not only in cardiovascular diseases but also in damages or dysfunctions of other organs. |
T31 |
9941-10070 |
Epistemic_statement |
denotes |
We can expect the further studies on ACE2 functions to contribute toward a new therapy for organ damages that target this enzyme. |
T32 |
10071-10151 |
Epistemic_statement |
denotes |
A recent report suggests that the Mas oncogene acts as a receptor for Ang-(1-7). |
T33 |
10774-10948 |
Epistemic_statement |
denotes |
36, 37 Recent studies suggest that Rac 1, c-Jun NH 2 -terminal kinase (JNK), p38 MAP kinase and the activation of phospholipase C might be involved in Mas-mediated signaling. |
T34 |
11052-11190 |
Epistemic_statement |
denotes |
Moreover, in cardiomyocytes, an inhibition of MAP kinase activation by Ang-(1-7) can be blocked by antisense oligonucleotides against Mas. |
T35 |
11191-11263 |
Epistemic_statement |
denotes |
38 More detailed research works can show the Mas functions more clearly. |
T36 |
11541-11631 |
Epistemic_statement |
denotes |
Moreover, the AT 2 -receptor agonists, such as compound 21, could be useful in the future. |
T37 |
11749-11879 |
Epistemic_statement |
denotes |
However, it has been clarified that this pathway acts as a counter-regulation system against the ACE-Ang II-AT 1 receptor pathway. |
T38 |
11880-12068 |
Epistemic_statement |
denotes |
Therefore, it is suggested that the ACE2-Ang-(1-7)-Mas axis could become a new target for the therapy of circulatory disorders and adult diseases, including that of the metabolic syndrome. |
T39 |
12069-12168 |
Epistemic_statement |
denotes |
The total effects of RAS seem to stand on the balance between ACE and ACE2 activities ( Figure 4) . |
T40 |
12169-12408 |
Epistemic_statement |
denotes |
In this respect, it could be considered that the classical ACE-Ang II-AT 1 receptor axis plays as a 'devil' and the 'ACE2-Ang-(1-7)-Mas axis' plays as an angel for fruitful aging in RAS through blood pressure lowering and organ protection. |